Details

Autor(en) / Beteiligte

• Meis, Paul J
• Klebanoff, Mark
• Thom, Elizabeth
• Dombrowski, Mitchell P
• Sibai, Baha
• Moawad, Atef H
• Spong, Catherine Y
• Hauth, John C
• Miodovnik, Menachem
• Varner, Michael W
• Leveno, Kenneth J
• Caritis, Steve N
• Iams, Jay D
• Wapner, Ronald J
• Conway, Deborah
• O'Sullivan, Mary J
• Carpenter, Marshall
• Mercer, Brian
• Ramin, Susan M
• Thorp, John M
• Peaceman, Alan M

Titel

Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate

Ist Teil von

• The New England journal of medicine, 2003-06, Vol.348 (24), p.2379-2385

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• Women with a history of preterm delivery are at high risk for recurrence in subsequent pregnancies, and an effective strategy to reduce this risk has been lacking. In this randomized, placebo-controlled trial, weekly injections of 17 alpha-hydroxyprogesterone caproate reduced the risk of delivery before 37 weeks of gestation by one third among such high-risk women. Injections of 17 alpha-hydroxyprogesterone reduced the risk among high-risk women. Preterm delivery — that is, delivery before 37 completed weeks of gestation — is the major determinant of infant mortality in developed countries. 1 Preterm delivery is more common in the United States than in many other developed countries and is the factor most responsible for the relatively high infant mortality in this country. 1 The rate of preterm delivery in the United States has increased progressively from 9 percent to 12 percent over the past two decades. 2 Despite many trials of reduced activity, tocolytic therapy, antibiotic therapy, and other strategies for prevention, no effective and reproducible method of preventing preterm delivery . . .